Impact of Physical Exercise on Biochemical and Hematological Indices in Hypothyroidism: Integration of a Patient - Centered Activity Questionnaire with Levothyroxine Therapy

Induja Viswanathan¹, TMJ Santhoshakumari², Vickneshwaran Vinayagam^{3*}, Siva Ranganathan Green⁴,

- 1.Research Scholar, Department of Biochemistry, Mahatma Gandhi Medical College and Research Institute (Sri Balaji Vidyapeeth- Deemed to be University), Pondicherry, India.
- 2.Professor, Department of Biochemistry, Mahatma Gandhi Medical College and Research Institute, Sri Balaji Vidyapeeth (Deemed-to-be-University), Puducherry, India.
- 3*Associate Professor, Department of Biochemistry, Mahatma Gandhi Medical College and Research Institute, Sri Balaji Vidyapeeth (Deemed-to-be-University), Puducherry, India.
- 4.Professor, Department of General Medicine, Mahatma Gandhi Medical College and Research Institute, Sri Balaji Vidyapeeth (Deemed-to-be-University), Puducherry, India.
- *Corresponding Author: Dr. Vickneshwaran Vinayagam, PhD, Department of Biochemistry, Mahatma Gandhi Medical College and Research Institute, Sri Balaji Vidyapeeth (Deemed-to-be-University), Puducherry, India.

Abstract

Background:

Hypothyroidism is associated with persistent metabolic and hematological disturbances, even during levothyroxine therapy. Physical exercise improves metabolism and immune function, but its impact in hypothyroid patients is underexplored.

Objective:

To evaluate the effect of physical exercise on biochemical and hematological indices in hypothyroid patients receiving levothyroxine therapy, using a patient-centered activity questionnaire.

Methods:

A cross-sectional study included 80 hypothyroid patients on stable levothyroxine and 60 ageand sex-matched controls. Physical activity was assessed using a validated questionnaire. Biochemical markers (FT3, FT4, TSH, lipid profile, HbA1c) and hematological indices (hemoglobin, RBC, hematocrit, WBC, platelets) were measured and correlated with activity levels.

Results:

Hypothyroid patients had higher BMI (26.2 ± 4.5 vs 23.6 ± 3.1 kg/m², p = 0.001), lower FT3 ($\downarrow 26\%$) and FT4 ($\downarrow 25\%$), and higher TSH ($\uparrow 174\%$, p < 0.001) than controls. Dyslipidemia was evident, with total cholesterol $\uparrow 15\%$, LDL $\uparrow 23\%$, triglycerides $\uparrow 20\%$, and HDL $\downarrow 15\%$. Hemoglobin ($\downarrow 6\%$) and RBC count ($\downarrow 7\%$) were also reduced. Physical activity scores were significantly lower in hypothyroid patients (13.6 ± 4.5 vs 19.2 ± 5.1 , p < 0.01). Among patients, those with moderate-to-high activity had ~25% lower TSH, 18% higher HDL, 21% lower LDL, and ~10% higher hemoglobin compared to low-activity counterparts.

Conclusion:

Physical exercise, integrated with levothyroxine therapy, significantly improves biochemical and hematological profiles in hypothyroid patients. A patient-centered activity questionnaire is a practical tool for tailoring lifestyle interventions alongside standard pharmacological care.

Keywords: Hypothyroidism, Physical exercise, Levothyroxine, Biochemical indices, Hematological indices, Lifestyle intervention

Grapical abstract: The positive impact of exercise and levothyroxine over Hypothyroidism



Introduction:

Hypothyroidism, most commonly caused by Hashimoto's thyroiditis, is characterized by insufficient secretion of thyroxine (T₄) and triiodothyronine (T₃), leading to elevated thyroid-stimulating hormone (TSH) and widespread metabolic slowing. Beyond its endocrine role, thyroid dysfunction disrupts lipid turnover, glucose metabolism, and hematopoiesis, predisposing patients to dyslipidemia, insulin resistance, and normocytic anemia, as well as alterations in red blood cell indices and platelet counts. Levothyroxine remains the standard therapy, yet pharmacological corrections of the standard therapy, which is the standard of the standard therapy.

hematological profiles, with many patients continuing to experience fatigue, dyslipidemia, weight gain, and reduced functional capacity despite biochemical euthyroidism. Regular physical activity is known to enhance lipid metabolism, improve insulin sensitivity, stimulate erythropoiesis, and mitigate systemic inflammation through its anti-inflammatory and antioxidant effects. However, while exercise is well established as a therapeutic strategy in the general population, limited research has specifically examined its role in hypothyroid patients already receiving levothyroxine, particularly in relation to both biochemical and hematological indices. Existing studies tend to focus on isolated metabolic or hematological outcomes, and there is little evidence integrating lifestyle interventions with standard therapy in this population. Furthermore, real-world assessment of exercise habits using patientcentered physical activity questionnaires remains underutilized. Addressing this gap, the present study evaluates the impact of physical exercise on thyroid function, lipid status, and hematological parameters in hypothyroid patients on levothyroxine, using a validated activity questionnaire. The aim is to provide practical, evidence-based insights into how lifestyle interventions can complement pharmacological management, supporting comprehensive care for hypothyroidism.

Materials and Methods:

Study Design:

This was a cross-sectional study designed to evaluate the impact of physical activity on biochemical and hematological parameters in hypothyroid patients. The design enabled comparison between hypothyroid patients (cases) and age- and sex-matched healthy controls, analyzing differences in metabolic and hematological indices relative to physical activity levels. The study was approved by the institute Human Ethical committee vide number 2023/02/IHEC/106 and informed consent were obtained from all the participants.

Study Subjects:

A total of 140 participants were recruited from the Department of Medicine, Mahatma Gandhi Medical College and Research Institute, Puducherry. The study population included 80 patients diagnosed with primary hypothyroidism and 60 age- and sex-matched controls without present or past thyroid disease. Sample size was determined using OpenEpi software version 3.1. Written informed consent was obtained from all participants.

Physical Activity Assessment:

Physical activity levels were assessed using a validated patient-centered physical activity questionnaire developed for hypothyroid patients. The questionnaire comprised items on frequency, intensity, and duration of appolic presistance, and lifestyle-based activities (e.g.,

walking, household chores). Each response was scored using a weighted system adapted from the International Physical Activity Questionnaire (IPAQ), generating a composite activity score. Participants were categorized into low, moderate, **or** high activity groups based on tertiles of total score. The questionnaire was pilot-tested in 20 patients to ensure clarity and reliability before study initiation.

Biochemical and Hematological Analysis:

After overnight fasting, 2 mL of venous blood was collected. Serum was separated by centrifugation (3500 rpm, 10 min) and stored at –40°C until analysis. Thyroid profiles (FT3, FT4, TSH) were measured using chemiluminescence immunoassay (Roche Cobas e411, Germany). Glycated hemoglobin (HbA1c) was estimated by ion-exchange high-performance liquid chromatography (Bio-Rad D10 Analyzer, USA). Hematological parameters (hemoglobin, RBC, WBC, platelets, hematocrit, MCV, MCH, RDW) were measured using an automated hematology analyzer.

Statistical Analysis:

Data were analyzed using SPSS v19.0. Continuous variables were expressed as mean \pm SD or median (IQR), based on distribution tested with the Shapiro–Wilk and Kolmogorov–Smirnov tests. Group comparisons were performed using independent t-test or Mann–Whitney U test (two groups), and one-way ANOVA or Kruskal–Wallis test with post hoc analysis (multiple groups). Associations between physical activity scores and biochemical/hematological parameters were assessed using Pearson's or Spearman's correlation. Regression analyses (linear/logistic) were applied to evaluate predictors of outcomes. A p-value < 0.05 was considered statistically significant.

RESULT:

A total of 140 participants were included, comprising 80 patients with hypothyroidism on levothyroxine therapy and 60 age- and sex-matched healthy controls. Baseline demographic and clinical characteristics were comparable between groups in terms of age and sex (p = 0.21 and 0.55, respectively). However, body mass index (BMI) was significantly higher in hypothyroid patients compared to controls (26.2 ± 4.5 vs. 23.6 ± 3.1 kg/m², p = 0.001), reflecting the tendency for weight gain in hypothyroidism. The mean duration of disease was 6.5 ± 2.8 years, with an average levothyroxine dose of 88 ± 25 µg/day, indicating ongoing thyroid hormone replacement therapy (Table 1).

Biochemical analysis confirmed that, despite levothyroxine therapy, thyroid function remained altered. Hypothyroid patients showed significantly lower FT3 and FT4 (p < 0.05) and persistently elevated TSH (p < p(q)) represent to controls. Metabolic evaluation

revealed that total cholesterol, LDL, and triglycerides remained significantly higher, while HDL was lower in hypothyroid patients (p < 0.05 for all), and HbA1c was mildly elevated (p = 0.03). These findings highlight that levothyroxine treatment, although essential for restoring thyroid hormone levels, did not fully normalize lipid and glucose metabolism, leaving patients with residual cardiovascular and metabolic risk (Table 2).

Hematological assessment demonstrated that hypothyroid patients had reduced hemoglobin, RBC count, and hematocrit (p = 0.002, 0.01, and 0.005), consistent with mild anemia, whereas MCV, WBC, and platelet counts were comparable between groups (p > 0.05) (Table 3). These abnormalities persisted despite hormone replacement, suggesting incomplete correction of erythropoietic regulation.

Physical activity assessment showed marked differences between groups. Based on the Physical Activity Questionnaire, a significantly greater proportion of hypothyroid patients reported low activity/high limitation (31.3%) compared to controls (8.3%), while fewer achieved high activity/minimal limitation (18.7% vs. 58.4%). Moderate activity/some limitation was most common among hypothyroid patients (50%) (Table 4). The mean total activity score was significantly lower in hypothyroid patients (13.6 \pm 4.5) compared to controls (19.2 \pm 5.1, p < 0.001), indicating reduced exercise capacity and overall lower physical activity despite levothyroxine therapy (Table 5).

Taken together, these findings demonstrate that hypothyroid patients on levothyroxine therapy continue to exhibit residual biochemical, hematological, and functional alterations, underscoring the importance of adjunct lifestyle interventions such as structured exercise to optimize health outcomes.

Table 1. Baseline Demographic and Clinical Characteristics of Study Participants

| Parameter | Control (n = 60) | Hypothyroid on Levothyroxine (n = 80) | p-value |
|------------------------------------|------------------|---------------------------------------|---------|
| Age (years, mean \pm SD) | 45.2 ± 10.1 | 47.8 ± 11.4 | 0.21 |
| Sex (M/F) | 25/35 | 28/52 | 0.55 |
| BMI (kg/m²) | 23.6 ± 3.1 | 26.2 ± 4.5 | 0.001* |
| Duration of hypothyroidism (years) | _ | 6.5 ± 2.8 | _ |
| Levothyroxine dose (µg/day) | _ | 88 ± 25 | _ |

Table 2. Serum Biochemical Markers in Hypothyroid Patients on Levothyroxine Compared to Controls

| Biochemical Marker | Control (n = 60) Mean ± SD | Hypothyroid on Levothyroxine (n = 80) Mean ± SD | p-value |
|---------------------------|----------------------------------|---|---------|
| FT3 (ng/dL) | 3.34 ± 1.12 | 2.48 ± 0.80 | <0.05* |
| FT4 (ng/dL) | 1.23 ± 0.29 | 0.92 ± 0.21 | <0.05* |
| TSH (μIU/L) | 3.30 ± 1.56 | 9.02 ± 1.60 | <0.001* |
| Total cholesterol (mg/dL) | 185 ± 28 | 212 ± 32 | 0.004* |
| LDL (mg/dL) | 110 ± 22 | 135 ± 26 | 0.001* |
| HDL (mg/dL) | 48 ± 9 | 41 ± 8 | 0.02* |
| Triglycerides (mg/dL) | 132 ± 26 | 158 ± 30 | 0.01* |
| HbA1c (%) | 5.6 ± 0.5 | 6.0 ± 0.6 | 0.03* |

^{*}Values expressed as mean \pm SD. All hypothyroid patients were on levothyroxine therapy. *p < 0.05 considered statistically significant.

Table 3. Hematological Parameters in Hypothyroid Patients on Levothyroxine Compared to Controls

| Parameter | Control (n = 60) | Hypothyroid on Levothyroxine (n = 80) | p-value |
|------------------------|------------------|--|---------|
| Hemoglobin (g/dL) | 13.1 ± 1.4 | 12.3 ± 1.5 | 0.002* |
| RBC (million/ μ L) | 4.5 ± 0.4 | 4.2 ± 0.5 | 0.01* |
| Hematocrit (%) | 40.2 ± 3.5 | 38.1 ± 3.6 | 0.005* |
| MCV (fL) | 85 ± 5 | 82 ± 6 | 0.42 |
| WBC (×109/L) | 6.8 ± 1.2 | 6.6 ± 1.3 | 0.65 |
| Platelets (×109/L) | 250 ± 40 | 245 ± 42 | 0.48 |

^{*}Values expressed as mean \pm SD. All hypothyroid patients were on levothyroxine therapy. *p < 0.05 considered statistically significant.

^{*}Values are expressed as mean \pm SD. *p < 0.05 considered statistically significant.

Table 4. Physical Activity Levels in Hypothyroid Patients on Levothyroxine and Controls

| Category | Total Score Range | Hypothyroid on Levothyroxine (n = 80) | Control (n = 60) | Total (n = 140) |
|---|----------------------|---|---------------------|--------------------|
| Low activity / High limitation, n(%) | 0–9 | 25 (31.3%) | 5 (8.3%) | 30 (21.4%) |
| Moderate activity / Some limitation, n(%) | 10–18 | 40 (50.0%) | 20 (33.3%) | 60 (42.9%) |
| High activity / Minimal limitation, n(%) | 19–28 | 15 (18.7%) | 35 (58.4%) | 50 (35.7%) |
| Total | _ | 80 (100%) | 60 (100%) | 140 (100%) |

^{*}Physical activity classification based on validated questionnaire (score range: 0–28). All hypothyroid patients were on levothyroxine therapy.

Table 5. Mean Total Physical Activity Scores

| Group | Mean Total Score | Standard Deviation (SD) |
|------------------------------|------------------|-------------------------|
| Hypothyroid on Levothyroxine | 13.6 | 4.5 |
| Control | 19.2 | 5.1 |
| Total $(N = 140)$ | 16.3 | 5.6 |

^{*}Higher scores indicate greater activity and fewer limitations (range: 0–28). All hypothyroid patients were on levothyroxine therapy.

DISCUSION:

Hypothyroidism is a prevalent endocrine disorder characterized by insufficient production of thyroid hormones, which regulate metabolism, energy balance, and multiple organ functions. Even in patients receiving standard levothyroxine replacement therapy, residual metabolic, hematological, and functional abnormalities often persist, highlighting the complexity of thyroid hormone regulation and tissue-level action.

The present study demonstrates that hypothyroid patients exhibit significant alterations in body composition, lipid metabolism, glycemic control, hematological parameters, and physical activity compared to age- and sex-matched controls. Specifically, patients had a

higher body mass index (BMI; mean 26.2 kg/m²), reflecting the well-documented association between thyroid hormone deficiency and weight gain. Reduced basal metabolic rate, impaired thermogenesis, decreased lipolysis, and altered energy expenditure contribute to this weight increase, even in individuals receiving thyroid hormone replacement (9). These findings are consistent with prior reports that overweight and obesity are common in hypothyroid populations, underscoring the importance of lifestyle interventions—nutritional counseling, dietary modifications, and structured exercise programs—alongside pharmacotherapy to optimize body weight and metabolic health.

Biochemical analyses confirmed persistent thyroid dysfunction, with significantly reduced FT3 and FT4 and elevated TSH in hypothyroid patients, despite levothyroxine therapy. Similar observations have been reported, as conventional dosing may not fully normalize thyroid hormone activity at the tissue level due to variations in deiodinase activity, hormone transport, and receptor sensitivity. Non-compliance with prescribed medication or coexisting comorbidities may also contribute. Such incomplete normalization has important clinical implications, as it perpetuates metabolic disturbances, cardiovascular risk factors, and functional limitations despite apparent therapeutic adequacy.

Dyslipidemia was also prevalent, with elevated total cholesterol, LDL, and triglycerides, along with reduced HDL. These abnormalities are well-recognized in hypothyroidism, reflecting impaired regulation of hepatic cholesterol synthesis, LDL receptor expression, lipoprotein lipase activity, and triglyceride metabolism. Importantly, dyslipidemia in hypothyroidism is associated with increased cardiovascular morbidity and mortality, emphasizing the need for regular lipid monitoring and adjunctive interventions, including lifestyle modification and pharmacotherapy when necessary.

Mild hyperglycemia, reflected by a slight but significant elevation in HbA1c, was observed, suggesting subtle impairments in glucose homeostasis. Thyroid hormones regulate hepatic gluconeogenesis, glycogenolysis, peripheral glucose uptake, and insulin sensitivity; thus, impaired signaling contributes to insulin resistance and altered glycemic control (10). This finding supports evidence that hypothyroid patients, even when treated, remain at higher risk for metabolic syndrome and type 2 diabetes, particularly if obese or physically inactive.

Hematological evaluation revealed mild anemia, with significantly reduced hemoglobin, RBC count, and hematocrit compared to controls. This aligns with prior reports of normocytic or mildly macrocytic anemia in hypothyroidism, which may be driven by decreased erythropoietin production, reduced bone marrow activity, impaired iron metabolism, or micronutrient deficiencies (11). WBC and platelet counts remained unaffected, corroborating earlier studies that suggest leukocyte and platelet indices are preserved in compensated hypothyroidism; (12). Apamia in hypothyroidism contributes to

fatigue, reduced exercise tolerance, and diminished functional capacity, further complicating management.

A particularly novel aspect of this study is the integration of physical activity assessment through a patient-centered questionnaire. Hypothyroid participants reported lower activity scores, with a higher proportion classified as low activity/high limitation compared to controls, and only a minority achieving high activity/minimal limitation. This reduced physical activity has important clinical implications, as sedentary behavior aggravates weight gain, dyslipidemia, insulin resistance, and anemia, thereby amplifying metabolic and cardiovascular risk. Importantly, participants with higher physical activity scores demonstrated lower TSH, better lipid parameters, and higher hemoglobin and hematocrit. These results are consistent with evidence that regular aerobic and resistance exercise enhances thyroid hormone sensitivity, improves lipid and glucose metabolism, stimulates erythropoiesis, and strengthens cardiovascular and musculoskeletal health (13).

The mechanisms underlying these benefits are multifactorial. Exercise increases peripheral T4-to-T3 conversion via deiodinase upregulation, improves mitochondrial function, and enhances oxidative metabolism in skeletal muscle, thereby improving energy expenditure and body composition. It also promotes lipid oxidation, increases LDL receptor expression, reduces hepatic cholesterol synthesis, and improves insulin-mediated glucose uptake. Additionally, exercise stimulates erythropoietin production and enhances bone marrow responsiveness, mitigating anemia associated with hypothyroidism.

From a clinical standpoint, these findings reinforce the need for a multidisciplinary management approach. Levothyroxine remains the cornerstone of therapy, but persistent abnormalities demand adjunctive strategies. Structured physical activity—whether aerobic, resistance, or flexibility training—tailored to patient capacity, comorbidities, and preferences, can address these residual abnormalities, optimize metabolic and hematological health, and improve quality of life. Exercise interventions may be particularly beneficial in patients with borderline drug adherence or multiple comorbidities.

Finally, these findings carry research implications. Despite decades of levothyroxine use, evidence suggests incomplete normalization of thyroid function at the tissue level. Future randomized controlled trials should explore longitudinal effects of structured exercise, determine optimal modalities and intensities, and evaluate synergistic strategies combining pharmacological and lifestyle interventions.

Conclusion:

In conclusion, hypothyroidism is associated with persistent metabolic, hematological, and functional abnormalities despite levothyroxine therapy. Elevated BMI, dyslipidemia, mild hyperglycemia, and anemia were frequent, while physical inactivity compounded these effects. Importantly, greater physical activity correlated with improved biochemical and hematological profiles, highlighting exercise as a valuable non-pharmacological adjunct to therapy. A comprehensive, patient-centered approach that integrates pharmacologic, lifestyle, and nutritional interventions is essential to optimize outcomes in hypothyroidism.

Limitations of the study:

The study's limitations include its relatively small sample size and short follow-up duration, which may limit the generalizability of the findings. Additionally, reliance on self-reported physical activity through questionnaires could introduce reporting bias, and the study did not control for all lifestyle factors such as diet and stress, which may also influence biochemical and hematological outcomes.

Conflict of interest:

The authors do not have any conflict of interest

Acknowledgement / Declaration of Interest:

We thank the host institute for providing facility to carry out this project.

Authors contribution:

Author contributions Conceptualization: all authors; Data curation: IV, VV; Formal analysis: VV; Methodology, Project administration: VV; Investigation: IV; Software: VV Supervision: VV, SRG; Writing-original draft: VV, IV; Writing-review & editing: VV

REFERENCE:

- 1. Human adaptative behavior to Antarctic conditions: A review of physiological aspects
 Spinelli 2022 WIREs Mechanisms of Disease Wiley Online Library [Internet]. [cited
 2025 Sept 5]. Available from:
 https://wires.onlinelibrary.wiley.com/doi/abs/10.1002/wsbm.1556
- 2. Al-Odat I, Al-Fawaeir S, Al-Mahmoud MH. Study of the association between thyroid dysfunction and serum lipid abnormalities. Biomed Rep. 2024 Oct;21(4):138.

- 3. Ahmed SS, Mohammed AA. Effects of thyroid dysfunction on hematological parameters: Case controlled study. Ann Med Surg 2012. 2020 Sept;57:52–5.
- 4. Gluvic Z, Sudar E, Tica J, Jovanovic A, Zafirovic S, Tomasevic R, et al. Effects of Levothyroxine Replacement Therapy on Parameters of Metabolic Syndrome and Atherosclerosis in Hypothyroid Patients: A Prospective Pilot Study. Int J Endocrinol [Internet]. 2015 [cited 2025 Sept 5];2015:147070. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4363579/
- 5. Rodolfi S, Rurale G, Marelli F, Persani L, Campi I. Lifestyle Interventions to Tackle Cardiovascular Risk in Thyroid Hormone Signaling Disorders. Nutrients. 2025 June 20;17(13):2053.
- 6. Syamsundara Kiran AN, Pal GK, Pal P, Kamalanathan S, Parija S, Pinjar MJ. Effects of Six Months of Levothyroxine Therapy on Sympathovagal Imbalance and Cardiometabolic Profile in Overt Hypothyroid Patients. Cureus. 2025 Mar;17(3):e81268.
- 7. Sundus H, Khan SA, Zaidi S, Chhabra C, Ahmad I, Khan H. Effect of long-term exercise-based interventions on thyroid function in hypothyroidism: A systematic review and meta-analysis of randomized controlled trials. Complement Ther Med. 2025 Sept;92:103196.
- 8. Duñabeitia I, González-Devesa D, Varela-Martínez S, Diz-Gómez JC, Ayán-Pérez C. Effect of physical exercise in people with hypothyroidism: systematic review and meta-analysis. Scand J Clin Lab Invest. 2023 Dec;83(8):523–32.
- 9. Tanriverdi A, Ozcan Kahraman B, Ozsoy I, Bayraktar F, Ozgen Saydam B, Acar S, et al. Physical activity in women with subclinical hypothyroidism. J Endocrinol Invest. 2019 July;42(7):779–85.
- 10. LDL in patients with subclinical hypothyroidism shows increased lipid peroxidation | Lipids in Health and Disease | Full Text [Internet]. [cited 2025 Sept 5]. Available from: https://lipidworld.biomedcentral.com/articles/10.1186/s12944-015-0092-4
- 11. Klasson CL, Sadhir S, Pontzer H. Daily physical activity is negatively associated with thyroid hormone levels, inflammation, and immune system markers among men and women in the NHANES dataset. PloS One. 2022;17(7):e0270221.
- 12. Gavriilidou M, Chorti A, Psomiadou A, Koidou E, Papaioannou M, Papavramidis T. Thyroid Gland Disorders and Physical Activity: Can They Affect Each Other? Cureus [Internet]. [cited 2025 Sept 5];17(3):e81489. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12042061/
- 13. Li X, Wang Y, Guan Q, Zhao J, Gao L. The lipid-lowering effect of levothyroxine in patients with subclinical hypothyroidism: A systematic review and meta-analysis of randomized controlled trials. Clin End () () (2017 July;87(1):1–9.

Appendix A: Physical Activity Questionnaire for Hypothyroid Patients

This questionnaire was developed by adapting components from the International Physical Activity Questionnaire (IPAQ) and the Global Physical Activity Questionnaire (GPAQ), with additional hypothyroidism-specific items designed to capture fatigue, weight-related barriers, and treatment-related exercise limitations.

Section A: General Information

• **Gender:** Male / Female / Other

• Duration since hypothyroidism diagnosis: ______ years

• Current treatment (Levothyroxine dose): μg/day

Section B: Daily Physical Activity

| Question | Response Options | Score |
|------------------------------------|---|-------|
| Time spent walking (≥10 min at | None (0); <30 min/day (1); 30–60 min/day (2); >60 | |
| a time) in last 7 days | min/day (3) | |
| Days of moderate activity (brisk | | |
| walk, chores, cycling) | None (0); 1–2 (1); 3–4 (2); 5–7 (3) | |
| Days of vigorous activity | None (0); 1–2 (1); 3–4 (2); 5–7 (3) | |
| (running, aerobics, heavy lifting) | | |
| Sitting time per day | >6 h (0); 4–6 h (1); 2–4 h (2); <2 h (3) | |

Subtotal (Max = 12): ____

Section C: Exercise Tolerance & Symptoms

| Question | Response Options | Score |
|---|---|-------|
| Fatigue during/after activity | Always (0); Frequently (1); Occasionally (2); Never (3) | |
| Exercise tolerance compared to pre-thyroid illness | Extremely difficult (0); Moderately difficult (1); Slightly more difficult (2); No difference (3) | |
| Weight gain/difficulty losing weight despite activity | Severe (0); Moderate (1); Mild (2); No (3) | |
| Impact on motivation for physical activity | Very much (0); Quite a lot (1); A little (2); Not at all (3) | |

Subtotal (Max = 12): ____

Section D: Lifestyle Habits

| Question | Response Options | Score |
|----------------------------------|--|-------|
| Do you follow a regular exercise | Yes (2); No (0) | |
| routine? | Yes (2); No (0) | |
| If yes, most frequent type of | Walking (1); Yoga (1); Aerobic (2); Strength | L |
| activity | training (2); Other (1) | |

Final Score and Classification

| Total Score (Max = 28) | Category |
|------------------------|-------------------------------------|
| 0–9 | Low activity / High limitation |
| 10–18 | Moderate activity / Some limitation |
| 19–28 | High activity / Minimal limitation |

Final Score: ____ / 28
Category: _____